Akeega® (niraparib and abiraterone acetate)
for Prostate Cancer
Akeega (niraparib and abiraterone acetate) is a prescription medicine used to treat metastatic castration-resistant prostate cancer (mCRPC) with an abnormal BRCA gene (BRCA-positive). It is combined with prednisone. Akeega is the first dual-action tablet combining a PARP inhibitor (niraparib) and an androgen biosynthesis inhibitor (abiraterone acetate). Niraparib blocks PARP, preventing cancer cell repair, while abiraterone blocks testosterone production, slowing cancer growth.
